Genmab A/S (GNMSF) Short Interest Ratio & Short Volume $220.72 +2.25 (+1.03%) (As of 11/1/2024 ET) Add Compare Share Share Short Interest Stock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Genmab A/S Short Interest DataGenmab A/S (GNMSF) has a short interest of 84,900 shares. This marks a -19.07% decrease in short interest from the previous month. The short interest ratio (days to cover) is 6.7, indicating that it would take 6.7 days of the average trading volume of 2,071 shares to cover all short positions.Current Short Interest84,900 sharesPrevious Short Interest104,900 sharesChange Vs. Previous Month-19.07%Dollar Volume Sold Short$19.93 millionShort Interest Ratio6.7 Days to CoverLast Record DateOctober 15, 2024Today's Trading Volume505 sharesAverage Trading Volume2,071 sharesToday's Volume Vs. Average24% Short Selling Genmab A/S? Sign up to receive the latest short interest report for Genmab A/S and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartGNMSF Short Interest Over TimeGNMSF Days to Cover Over TimeGNMSF Percentage of Float Shorted Over Time Ad Chaikin AnalyticsSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA). Genmab A/S Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/15/202484,900 shares $19.93 million -19.1%N/A6.7 $234.80 9/30/2024104,900 shares $24.61 million -50.8%N/A80.7 $234.65 9/15/2024213,000 shares $55.32 million +3.3%N/A142 $259.72 8/31/2024206,200 shares $56.67 million +11.1%N/A114.6 $274.83 8/15/2024185,600 shares $49.24 million -1.2%N/A44.2 $265.28 7/31/2024187,900 shares $52.13 million +4.0%N/A19.4 $277.44 Get the Latest News and Ratings for GNMSF and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter. 7/15/2024180,700 shares $46.58 million +19.5%N/A106.3 $257.77 6/30/2024151,200 shares $37.12 million +28.2%N/A116.3 $245.49 6/15/2024117,900 shares $30.47 million -0.6%N/A107.2 $258.44 5/31/2024118,600 shares $32.69 million +9.0%N/A107.8 $275.67 5/15/2024108,800 shares $31.72 million -49.4%N/A181.3 $291.54 4/30/2024214,900 shares $58.93 million +26.6%N/A126.4 $274.22 4/15/2024169,700 shares $47.86 million +7.3%N/A169.7 $282.00 3/31/2024158,100 shares $48.47 million -3.5%N/A175.7 $306.59 3/15/2024163,800 shares $49.40 million -4.1%N/A136.5 $301.60 2/29/2024170,800 shares $47.55 million +24.1%N/A27.5 $278.41 2/15/2024137,600 shares $39.55 million -11.6%N/A86 $287.40 1/15/202430,700 shares $9.65 million -4.7%N/A16.2 $314.40 12/31/202332,200 shares $10.17 million -1.5%N/A16 $315.70 12/15/202332,700 shares $10.19 million +1.6%N/A12.1 $311.50 11/30/202332,200 shares $10.27 million -42.7%N/A16.9 $319.00 11/15/202356,200 shares $18.21 million +102.2%N/A25.5 $324.07 10/31/202327,800 shares $7.98 million +1.1%N/A23.2 $287.10 10/15/202327,500 shares $8.77 million +10.0%N/A45.8 $319.00 9/30/202325,000 shares $8.91 million +113.7%N/A41.7 $356.30 9/15/202311,700 shares $4.40 million -0.9%N/A7.8 $376.20 8/31/202311,800 shares $4.47 million +6.3%N/A15.6 $379.20 8/15/202311,100 shares $4.09 million -31.5%N/A27.8 $368.40 7/31/202316,200 shares $6.65 million -38.2%N/A23.1 $410.40 7/15/202326,200 shares $10.36 million -36.7%N/A18.7 $395.43 6/30/202341,400 shares $15.51 million +19.7%N/A37.6 $374.57 6/15/202334,600 shares $13.30 million -5.5%N/A38.4 $384.50 5/31/202336,600 shares $14.46 million -42.6%N/A73.2 $394.99 5/15/202363,800 shares $27.06 million +69.2%N/A91.1 $424.10 4/30/202337,700 shares $15.41 million -37.5%N/A75.4 $408.70 4/15/202360,300 shares $24.87 million -28.4%N/A67 $412.50 3/31/202384,200 shares $31.47 million -18.7%N/A210.5 $373.75 3/15/2023103,600 shares $36.80 million +143.2%N/A172.7 $355.25 2/28/202342,600 shares $15.90 million -56.0%N/A60.9 $373.25 2/15/202396,900 shares $38.21 million +8.8%N/A193.8 $394.30625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here 1/31/202389,100 shares $34.93 million -3.3%N/A148.5 $392.00 1/15/202392,100 shares $37.12 million +37.3%N/A153.5 $403.00 12/30/202267,100 shares $28.69 million +527.1%N/A41.9 $427.50 12/15/202210,700 shares $4.77 million +78.3%N/A3.8 $445.52 11/30/20226,000 shares $2.75 million -25.0%N/A10 $457.50 11/15/20228,000 shares $3.38 million +14.3%N/A6.7 $422.43 10/31/20227,000 shares $2.69 million -51.7%N/A0.8 $384.30 10/15/202214,500 shares $5.35 million +20.8%N/A11.2 $368.80 9/30/202212,000 shares $3.84 million +10.1%N/A10.9 $320.21 9/15/202210,900 shares $3.88 million -71.7%N/A7.8 $356.25 8/31/202238,500 shares $13.59 million -31.0%N/A55 $353.01 8/15/202255,800 shares $20.85 million +30.1%N/A27.9 $373.61 7/31/202242,900 shares $14.95 million +257.5%N/A39 $348.50 7/15/202212,000 shares $4.09 million -87.2%N/A7.1 $341.16 6/30/202294,000 shares $30.58 million -30.0%N/A16.2 $325.29 6/15/2022134,200 shares $36.61 million +63.7%N/A63.9 $272.80 5/31/202282,000 shares $24.77 million -60.0%N/A8 $302.08 5/15/2022204,900 shares $59.57 million +7.1%N/A113.8 $290.75 4/30/2022191,300 shares $69.71 million +92.7%N/A273.3 $364.42 4/15/202299,300 shares $36.64 million +95.9%N/A66.2 $368.95 3/31/202250,700 shares $18.10 million -4.7%N/A56.3 $357.10 3/15/202253,200 shares $18.22 million -23.8%N/A44.3 $342.42 2/28/202269,800 shares $23.25 million +13.1%N/A34.9 $333.03 2/15/202261,700 shares $20.30 million +5.5%N/A26.8 $328.98 1/31/202258,500 shares $20.03 million +290.0%N/A26.6 $342.38 1/15/202215,000 shares $5.16 million -38.3%N/A10 $344.28 12/31/202124,300 shares $9.49 million -66.7%N/A24.3 $390.53 12/15/202172,900 shares $27.46 million +74.0%N/A11.4 $376.72 11/30/202141,900 shares $15.97 million -17.8%N/A41.9 $381.08 11/15/202151,000 shares $21.14 million +351.3%N/A85 $414.58 10/29/202111,300 shares $5.09 million -33.5%N/A7.1 $450.50 10/15/202117,000 shares $7.60 million +33.9%N/A24.3 $446.95 9/30/202112,700 shares $5.37 million -11.8%N/A25.4 $423.08 9/15/202114,400 shares $6.08 million +25.2%N/A13.1 $422.08 8/31/202111,500 shares $5.49 million +0.9%N/A28.8 $477.57 8/13/202111,400 shares $5.18 million +22.6%N/A16.3 $454.38 7/30/20219,300 shares $4.17 million +34.8%N/A5.2 $448.87 7/15/20216,900 shares $3.03 million -13.8%N/A11.5 $438.47 6/30/20218,000 shares $3.38 million -31.6%N/A6.7 $422.32 6/15/202111,700 shares $5.10 million -58.4%N/A14.6 $435.68 5/28/202128,100 shares $11.52 million -64.5%N/A56.2 $409.92 5/14/202179,100 shares $29.48 million -26.7%N/A197.8 $372.72 4/30/2021107,900 shares $40.45 million +6.6%N/A269.8 $374.92 4/15/2021101,200 shares $35.77 million +19.8%N/A44 $353.50 3/31/202184,500 shares $26.73 million +14.8%N/A24.9 $316.28 3/15/202173,600 shares $23.74 million +46.0%N/A73.6 $322.50 2/26/202150,400 shares $17.39 million -40.1%N/A16.8 $345.00 2/12/202184,100 shares $34.26 million +557.0%N/A120.1 $407.32 1/29/202112,800 shares $5.26 million +12.3%N/A8 $411.00 1/15/202122,900 shares $10.04 million +97.4%N/A45.8 $438.42Ex WH Advisor Who Predicted Biden Leaving Race Makes Startling New Prediction (Ad)Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… 12/31/202029,700 shares $12.01 million +29.7%N/A74.3 $404.45 12/15/202022,900 shares $8.95 million +97.4%N/A45.8 $390.69 11/30/202011,600 shares $4.35 million -11.5%N/A9.7 $375.01 11/15/202013,100 shares $4.81 million +13.9%N/A14.6 $366.96 10/30/202011,500 shares $3.98 million No ChangeN/A12.8 $346.21 10/15/202011,500 shares $4.43 million -35.0%N/A38.3 $385.31 9/30/202017,700 shares $6.50 million -80.7%N/A14.8 $367.16 9/15/202091,800 shares $34.27 million +37.2%N/A76.5 $373.30 8/31/202066,900 shares $25.24 million +5.5%N/A47.8 $377.29 8/14/202063,400 shares $23.14 million -11.3%N/A52.8 $365.04 7/31/202071,500 shares $23.95 million -0.4%N/A102.1 $334.90 7/15/202071,800 shares $25.35 million -30.5%N/A102.6 $353.00 6/30/2020103,300 shares $34.61 million +1.3%N/A41.3 $335.05 6/15/2020102,000 shares $30.67 million +49.1%N/A8.9 $300.71 5/29/202068,400 shares $21.41 million +25.5%N/A6.3 $313.00 5/15/202054,500 shares $15.26 million +0.2%N/A13.3 $280.00 4/30/202054,400 shares $12.78 million -43.0%N/A21.8 $235.00 4/15/202095,500 shares $20.49 million +92.2%N/A31.8 $214.54 3/31/202049,700 shares $11.83 million +208.7%N/A35.5 $238.00 3/13/202016,100 shares $2.88 million -82.2%N/A10.7 $179.05 2/28/202090,500 shares $21.04 million -4.5%N/A60.3 $232.50 2/14/202094,800 shares $20.01 million -50.1%N/A94.8 $211.04 1/31/2020189,800 shares $45.55 million -28.1%N/A135.6 $240.00 1/15/2020264,000 shares $64.01 million +4.3%N/A1320 $242.48 12/31/2019253,100 shares $57.50 million -26.3%N/A230.1 $227.20 GNMSF Short Interest - Frequently Asked Questions What is Genmab A/S's current short interest? Short interest is the volume of Genmab A/S shares that have been sold short but have not yet been closed out or covered. As of October 15th, traders have sold 84,900 shares of GNMSF short. Learn More on Genmab A/S's current short interest. What is a good short interest ratio for Genmab A/S? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. GNMSF shares currently have a short interest ratio of 7.0. Learn More on Genmab A/S's short interest ratio. Is Genmab A/S's short interest increasing or decreasing? Genmab A/S saw a decline in short interest in the month of October. As of October 15th, there was short interest totaling 84,900 shares, a decline of 19.1% from the previous total of 104,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Genmab A/S's short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Genmab A/S: Takeda Pharmaceutical Company Limited (0.23%), BioNTech SE (1.02%), BeiGene, Ltd. (1.55%), Moderna, Inc. (9.70%), Teva Pharmaceutical Industries Limited (1.76%), Summit Therapeutics Inc. (2.10%), Genmab A/S (0.30%), Viatris Inc. (1.93%), Dr. Reddy's Laboratories Limited (1.32%), Sarepta Therapeutics, Inc. (5.93%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.14 billion), AppLovin Co. ($3.15 billion), Paychex, Inc. ($2.69 billion), Nu Holdings Ltd. ($2.48 billion), Cencora, Inc. ($2.24 billion), International Paper ($2.04 billion), Tractor Supply ($1.96 billion), Coinbase Global, Inc. ($1.93 billion), Moderna, Inc. ($1.91 billion), and SoFi Technologies, Inc. ($1.84 billion). View all of the most shorted stocks. What does it mean to sell short Genmab A/S stock? Short selling GNMSF is an investing strategy that aims to generate trading profit from Genmab A/S as its price is falling. GNMSF shares are trading up $2.25 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Genmab A/S? A short squeeze for Genmab A/S occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of GNMSF, which in turn drives the price of the stock up even further. How often is Genmab A/S's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GNMSF, twice per month. The most recent reporting period available is October, 15 2024. More Short Interest Resources from MarketBeat Related Companies TAK Short Interest BNTX Short Interest BGNE Short Interest MRNA Short Interest TEVA Short Interest SMMT Short Interest GMAB Short Interest VTRS Short Interest RDY Short Interest SRPT Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (OTCMKTS:GNMSF) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Genmab A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
